Announcements Trials

Browse Landscape

Phase

Phase 2 27 Phase NA 6 Phase 1/2 6 Phase 1 6 Phase 3 4 Phase 4 1 Phase 2/3 1

Status

Recruiting 3 Withdrawn 1 Unknown 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 1 Intellectual Disability 1 Autistic Disorder 1

Interventions

Cisplatin 20 Docetaxel 19 Capecitabine 19 Oxaliplatin 14 Drug Therapy 14 Cyclophosphamide 14 Paclitaxel 13 Fluorouracil 12 Radiotherapy 11 apatinib 9 Gemcitabine 9 Doxorubicin 9 Decitabine 9 Methotrexate 8 Epirubicin 8 Carboplatin 8 sintilimab 6 Etoposide 6 camrelizumab 5 anlotinib 5 XELOX 5 Sorafenib 5 Radiation 5 Pemetrexed 5 Neoadjuvant Therapy 5 Leucovorin 5 Idarubicin 5 Dexamethasone 5 Cytarabine 5 Busulfan 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Unknown × Everolimus × Clear all

NCT01730209 2015-05-05

RAPIT

Erasmus Medical Center

Phase 2/3 Unknown

Autistic Disorder, Intellectual Disability, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡